Systemic lupus erythematosus and active lupus nephritis research hub

LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy

This study tests a new medicine called cenerimod for adults with lupus and active kidney inflammation (lupus nephritis). Researchers want to see if adding cenerimod to standard treatments helps protect the kidneys, reduces protein in the urine, and lowers the need for steroid medicines over 76 weeks.